Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR in its latest market analysis forecasts that the atherosclerosis drugs market will register a healthy compound annual growth rate between 2021 and 2031.
Combating Atherosclerosis with Targeted Nanomedicines Gaining Traction Worldwide
A Fact.MR survey on atherosclerosis drugs market offers detailed analysis on growth drivers and trends affecting demand in terms of drug class, distribution channel and region. It also highlights various strategies adopted by key market players to gain a competitive edge in the atherosclerosis drugs market.
Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR in its latest market analysis forecasts that the atherosclerosis drugs market will register a healthy compound annual growth rate (CAGR) between 2021 and 2031. With soaring demand for new medicines, the sales of atherosclerosis drugs have considerably increased.
Increasing prevalence of atherosclerotic cardiovascular diseases, sedentary lifestyle, rising geriatric population and growing demand for atherosclerosis drugs are some of the major factors driving the global market.
According to the World Health Organization (WHO), around 17.9 million people die each year from cardiovascular diseases (CVDs). This creates huge demand for atherosclerosis drugs.
The highly effective nature of atherosclerosis drugs makes them ideal for the treatment of cardiovascular diseases. These drugs help to reduce cholesterol level and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.
Technological advancements in nanotechnology have completely transformed the atherosclerosis drugs market. Introduction of nanomedicines as a novel tool for enhanced drug delivery, imaging and diagnosis strategies has shown promising results to combat cardiovascular diseases. Manufacturers are focusing on developing new nanoparticle drug combinations for the treatment of atherosclerosis.
Growing awareness among people regarding atherosclerosis and its treatments also plays a vital role in expanding the market. Similarly, high penetration of generic drugs, especially across developing and underdeveloped nations is positively impacting the market.
Various initiatives launched by government and other healthcare organization along with the expanding healthcare infrastructure will bode well for the market.
Owing to the increasing prevalence of obesity, hypercholesterolemia and other cardiovascular diseases, cholesterol lowering medication remains the top selling product and the trend is likely to continue in the future.
North America dominates the atherosclerosis drugs market with a healthy share. The growth in the region can be attributed to the rising cases of atherosclerosis, presence of leading drug companies and continuous FDA drug approvals.
“Continuous advancements in drug delivery systems are creating lucrative opportunities for the leading manufacturers. Besides this, the rising awareness among people regarding atherosclerosis and the availability of various treatments will bode well for the market” says the Fact.MR analyst.
For More Information On How To Improve Your Atherosclerosis Drugs Market Footprint, Request A Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=4434
Key Takeaways from Atherosclerosis Drugs Market Survey
- With increasing prevalence of cardiovascular diseases and presence of leading market players, North America will continue to dominate the atherosclerosis drugs market. The North America market is projected to account for around 34% market share by 2031.
- Asia Pacific will emerge as a highly lucrative market for atherosclerosis drugs. This can be attributed to the increasing penetration of generic drugs and growing awareness among people regarding atherosclerosis and its treatment.
- Europe market is witnessing positive growth on the back of increasing patient pool, rising geriatric population and sedentary lifestyle.
- Cholesterol lowering medications category leads the market with a healthy share due to high prevalence of cardiovascular disease.
- Hospital pharmacies are projected to account for around 46% share in the atherosclerosis drugs market by 2031.
Key Drivers
- Increasing prevalence of atherosclerosis and other heart diseases is driving the atherosclerosis drugs market.
- High penetration of generic atherosclerosis drugs is positively impacting the market growth.
- Growing awareness regarding atherosclerosis and its treatments will create lucrative growth opportunities for the manufactures during the forecast period.
- Rising geriatric population, sedentary lifestyle and high consumption of alcohol will expand the atherosclerosis drugs market further during the forecast period.
Key Restraints
- Side effects associated with atherosclerosis drugs is hampering the market growth.
- Low diagnostic rates also limit the market growth.
Ask Your Atherosclerosis Drugs Market Related Questions & Get Customized Reports
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4434
Competitive Landscape
Key players operating in the atherosclerosis drugs market are focusing on expanding their products portfolio by means of new drug launches and drug approvals. They are adopting various organic and inorganic growth strategies such as mergers, advanced drug developments, partnerships and collaborations to gain a competitive edge in the market.
- In June 2020, the Korea Advanced Institute of Science and Technology (KAIST) designed physiochemical cargo-switching nano-particles (CSNP) for the treatment of atherosclerosis.
- In June 2020, Novartis completes the acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran.
- In April 2021, FDA approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol.
Some of the prominent players operating in the atherosclerosis drugs market profiled by Fact.MR are:
- Pfizer Inc.
- GlaxoSmithKline PLC
- Amgen Inc.
- Sanofi
- Mylan N.V.
- F.Hoffmann-La Roche Ltd.
- Janssen Pharmaceuticals, Inc.
- Bayer AG
- Merck & Co., Inc.
- Novartis AG.
More Insights on the Global Atherosclerosis Drugs Sales Outlook
Fact.MR provides an unbiased analysis of atherosclerosis drugs market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for atherosclerosis drugs with a detailed segmentation on the basis of:
Drug Class
- Anti-platelet Medications
- Cholesterol Lowering Medications
- Fibric Acid and Omega-3 Fatty Acid Derivatives
- Beta Blockers
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Calcium Channel Blockers
- Diuretics
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Questions Covered in the Atherosclerosis Drugs Sales Outlook Report
- The report offers insight into atherosclerosis drugs demand outlook for 2021-2031
- The market study also highlights projected sales growth for atherosclerosis drugs market between 2021 and 2031
- Atherosclerosis drugs market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Atherosclerosis drugs market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain
OTC Analgesics Market - With the wide availability of drugs for relieving various types of pain in distribution stores, OTC analgesic drugs are typically purchased in large quantities. These factors are expected to have an impact on the global OTC analgesics market’s growth. The availability of over-the-counter analgesics has made it easier and more convenient to manage pain symptoms, and these are now prescribed in conjunction with approved drugs as maintenance therapies.
OTC Vitamins & Dietary Supplements Market – Fact.MR’s recent report on the OTC vitamins and dietary supplements market is the result of extensive and thorough research methodology. By function, the use of over-the-counter vitamins and dietary supplements is expected to be robust for maintaining overall body well-being. Throughout the forecast period, global market revenue from OTC vitamins and dietary supplements for general well-being is expected to account for the lion’s share.
Generic Injectables Market - The large molecular injectables segment is expected to account for three-fifths of the total market value in the global generic injectables market. Rising demand for affordable biological products, accelerated R&D activities for biosimilar products, and the expected patent expiration of blockbuster molecules by 2020 are key drivers. During the forecast period, large molecular injectable drugs are expected to grow at a stellar CAGR of 34.8%.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR